Global Med Technologies(R) Announces U.S. Release of Proven Tissue and Cellular Therapy Product
July 08 2008 - 10:00AM
PR Newswire (US)
Recent Inlog Acquisition Provides Established Cellular Therapy
Solution DENVER, July 8 /PRNewswire-FirstCall/ -- Global Med
Technologies(R), Inc. ("Global Med" or "the Company") (OTC:GLOB)
(BULLETIN BOARD: GLOB) , an international e-Health, medical
information technology company, today announced the immediate
release in the United States of EdgeCell(TM), a proven cellular
therapy software solution for tissue banks, stem cell laboratories
and cord blood banks. EdgeCell, with an installed base in Europe,
will provide U.S. customers with an established Cellular Therapy
product that has been meeting the needs of a variety of European
customers. (Logo:
http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO)
EdgeCell is a state-of-the-art Cellular Therapy software solution
for hospitals, surgery centers and health care facilities. EdgeCell
fully tracks the procurement process including the medical history
questionnaire; any required testing including specimen reception
and infectious disease testing; product preparation including
packaging, labeling and storage as well as crossmatching and
distribution. Along with an extensive list of safety features,
EdgeCell incorporates full traceability and generation of
regulatory documentation. The complex nature of tissue banks, stem
cell laboratories and cord blood banks dictates that distinct
business rules and parameters be tailored to each type of product.
EdgeCell meets this need through its ability to configure and
maintain distinct business rules and parameters for each type of
product be it tissue (bone parts, whole bone, cells, valves,
cornea, skin, and other tissues), stem cells or cord blood. Inlog
has the ISO 9001:2000 and NSF/ISO 25051/12119 certification for
EdgeCell and its other products assuring the highest level of
quality regarding the design, testing and validation of the
software, the documentation of the software and the quality of
support and maintenance. Raphael Bardonnet, M.D., Director of the
BioBank in Paris, France, stated, "BioBank required a software
solution that could meet our evolving needs as we develop new
technologies for the preparation and processing of our biologics.
We looked to Inlog, one of the European leaders in blood
transfusion and medical software, for our tissue banking needs. For
us, it was the logical choice because of Inlog's high quality
standards and the ease with which EdgeCell can be configured for
the multiple tissue types that we procure and the unique processes
we use to prepare, test, store and distribute." Dr. Bardonnet went
on to state, "As our researchers continue to develop innovative
methods to prepare our products, EdgeCell can be easily adapted,
without custom software development, to fully track our new
processes including equipment and ancillary products that were
used. We have been very satisfied with the reliability and ease of
use in the EdgeCell client server graphical software application."
Thomas F. Marcinek, President and COO of Global Med Technologies,
stated, "We are very proud to offer EdgeCell for sale in the United
States. When we made the announcement at our annual User Group
meeting, our customers were very excited to hear about the imminent
availability of a proven cellular therapy solution with an
established customer base. EdgeCell is a product of Global Med's
recent acquisition of Inlog, a leading provider of medical
technology solutions with customers at 700 sites in 15 European,
African and Middle Eastern countries." Mr. Marcinek added, "We know
the need for software solutions such as EdgeCell is rapidly
increasing as more hospitals enter the emerging tissue
transplantation market. With a global target market of more than
10,000 hospitals and surgical centers, we see EdgeCell as a growth
platform that will greatly enhance our domestic and international
expansion. We are confident in this product and its ability to
provide the quality transplant management software our customers
and potential customers have been seeking. As a forerunner in this
essential technology, we are poised to satisfy the growing demand
for proven biologic transplant management systems and to grow our
global presence as a provider of quality healthcare software
solutions." About Global Med Technologies, Inc. Global Med
Technologies(R), Inc. is an international medical software company
which develops regulated and non-regulated software products and
services for the healthcare industry. As a leading provider of
blood and laboratory software applications and services, Global
Med's products are deployed in 20 countries and serve over 1,400
transfusion centers, blood banks and laboratories. Global Med's
U.S. division, Wyndgate Technologies(R), provides Vein-to-Vein(R)
tracking through its Donor Doc(TM), SafeTrace(R), SafeTrace Tx(R)
and ElDorado Donor(TM) software products. Each year, Wyndgate's
products and services manage more than eight million blood
components, representing over 27% of the U.S. blood supply. Global
Med's European subsidiary, Inlog, SA, is a leading provider of
donor center and transfusion management systems as well as cellular
therapy software, laboratory information systems and quality
assurance medical software systems internationally. Inlog's
products include EdgeBlood**, EdgeTrack**, EdgeCell, EdgeLab and
SAPA. Global Med's U.S. subsidiary, PeopleMed(R), Inc., provides
cost-effective customized software validation, consulting and
compliance solutions to hospitals and donor centers. For more
information about Global Med's products and services, please call
800-996-3428 or visit http://www.globalmedtech.com/,
http://www.peoplemed.com/, http://www.inlog.com/ and
http://www.wyndgate.com/. **FDA 510(k) clearance required prior to
sales in the U.S. This news release may include statements that
constitute forward-looking statements, usually containing the words
"believe," "estimate," "project," "expects" or similar expressions.
These statements are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. By making these
forward-looking statements, the Company undertakes no obligation to
update these statements for revisions or changes after the date of
this news release.
http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO
http://photoarchive.ap.org/ DATASOURCE: Global Med Technologies,
Inc. CONTACT: Michael I. Ruxin, M.D., of Global Med Technologies,
Inc., +1-303-238-2000, ; or investors, Paul Holm, President of
portfoliopr, +1-212-999-5585, , for Global Med Technologies, Inc.
Web site: http://www.globalmedtech.com/
Copyright